Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maja Stanojevic

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Plos One|April 12, 2014
Patterns of transmitted HIV drug resistance in Europe vary by risk groupDineke Frentz, David van de Vijver, Ana Abecasis, et al.
Blood|December 17, 2020
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane proteinMichael D Keller, Katherine M Harris, Mariah A Jensen-Wachspress, et al.
Retrovirology|October 4, 2012
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patientsKristof Theys, Koen Deforche, Jurgen Vercauteren, et al.
The Journal of Infectious Diseases|July 3, 2015
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)Lucas Etienne Hermans, Valentina Svicher, Suzan Diepstraten Pas, et al.
Retrovirology|January 16, 2013
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemicsAna B Abecasis, Annemarie M J Wensing, Dimitris Paraskevis, et al.
Retrovirology|April 5, 2013
Limited cross-border infections in patients newly diagnosed with HIV in EuropeDineke Frentz, Annemarie M J Wensing, Jan Albert, et al.
BMC Infectious Diseases|June 3, 2018
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in EuropeLuna Colagrossi, Lucas E Hermans, Romina Salpini, et al.
BMC Infectious Diseases|July 23, 2014
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in EuropeDineke Frentz, David A M C Van de Vijver, Ana B Abecasis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2006
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypesDavid A van de Vijver, Annemarie M J Wensing, Gioacchino Angarano, et al.
The Journal of Infectious Diseases|August 19, 2005
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical managementAnnemarie M J Wensing, David A van de Vijver, Gioacchino Angarano, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Plos One|April 12, 2014
Patterns of transmitted HIV drug resistance in Europe vary by risk groupDineke Frentz, David van de Vijver, Ana Abecasis, et al.
Blood|December 17, 2020
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane proteinMichael D Keller, Katherine M Harris, Mariah A Jensen-Wachspress, et al.
Retrovirology|October 4, 2012
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patientsKristof Theys, Koen Deforche, Jurgen Vercauteren, et al.
The Journal of Infectious Diseases|July 3, 2015
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)Lucas Etienne Hermans, Valentina Svicher, Suzan Diepstraten Pas, et al.
Retrovirology|January 16, 2013
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemicsAna B Abecasis, Annemarie M J Wensing, Dimitris Paraskevis, et al.
Retrovirology|April 5, 2013
Limited cross-border infections in patients newly diagnosed with HIV in EuropeDineke Frentz, Annemarie M J Wensing, Jan Albert, et al.
BMC Infectious Diseases|June 3, 2018
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in EuropeLuna Colagrossi, Lucas E Hermans, Romina Salpini, et al.
BMC Infectious Diseases|July 23, 2014
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in EuropeDineke Frentz, David A M C Van de Vijver, Ana B Abecasis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2006
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypesDavid A van de Vijver, Annemarie M J Wensing, Gioacchino Angarano, et al.
The Journal of Infectious Diseases|August 19, 2005
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical managementAnnemarie M J Wensing, David A van de Vijver, Gioacchino Angarano, et al.
Pageof 6